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Renal dysfunction is a common and serious complication in
multiple myeloma (MM) patients. Renal proximal tubule
injury is characteristic in MM, and may result in disturbed
renal handling of various vitamins. The abnormal excretion of
vitamins in urine may result in their low serum levels. The
goal of this study was to investigate the urinary excretion of
retinol in MM and its relationship with serum retinol
concentration. For this purpose, 24 MM patients and 10
healthy individuals were studied. Serum and urinary retinol
and retinol-binding protein (RBP) were measured by the
high-performance liquid chromatography method and
enzyme-linked immunosorbent assay, respectively. The study
showed that 58% of MM patients excreted retinol in urine,
while only 29% had elevated serum creatinine (Po0.05).
There was a strong and highly significant correlation
between urinary retinol and RBP (r¼ 0.973, Po0.006).
Patients with normal and mildly elevated serum creatinine
who excreted retinol in urine had a marked decrease in
serum retinol (Po0.007). On the other hand, serum retinol
was not decreased in patients with moderate or severe renal
failure, despite its urinary loss. Our data indicate that
(i) urinary retinol is a more frequent marker of renal
dysfunction than elevated serum creatinine in MM patients,
(ii) serum retinol is decreased in MM with normal or mildly
elevated serum creatinine, but not in patients with
moderate/severe renal failure, and (iii) urinary retinol may
serve as a diagnostic marker of renal proximal tubule
dysfunction in MM patients.
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Renal dysfunction is a common and serious complication
in patients suffering from multiple myeloma (MM): about
50% of newly diagnosed MM patients have renal failure,1
and renal failure is the second most common cause of
death in myeloma, surpassed only by infections.2 Early
accurate diagnosis of the renal alterations in MM patients
may significantly impact morbidity and survival.2,3 The
etiology of renal damage in MM is multifactorial, but a
central role is attributed to free monoclonal light chains
(Bence Jones protein). The capacity of kidney proximal
tubular cells to reabsorb and catabolize Bence Jones protein
is exceeded in MM, resulting in proximal tubule atrophy
and distal tubule cast formation.4 Also, some Bence Jones
proteins are directly toxic to the renal proximal tubule.5
Renal proximal tubule cells are very important for the
metabolism and homeostasis of vitamins.6 Low serum
concentrations of retinol, and vitamins D and B12, which
have been documented in MM patients,7–9 might be a
consequence of the renal dysfunction. Leheste et al.10 showed
that MM patients who developed Fanconi syndrome
excreted retinol and large quantities of 25-OH vitamin
D3 in urine, while healthy subjects had no retinol in urine,
and excreted substantially less quantities of 25-OH vitamin
D3. Recently, we reported preliminary results on retinol
excretion in the urine of patients who suffered from MM
and who did not have Fanconi syndrome.11 The literature
data and our own findings support the concept that the
renal handling and homeostasis of retinol and other vitamins
are disturbed in MM patients. The goal of the present
study was to investigate the urinary excretion of retinol in
patients with MM, and its relation to serum retinol
concentration. An additional aim was to evaluate the
diagnostic value of the urinary retinol measurement in MM
patients.
RESULTS
Data obtained in the control group are summarized in
Table 1. None of the healthy subjects excreted detectable
quantities of retinol in urine.
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Nine of the 24 MM patients had IgG k, nine had IgG l,
two had IgA k and two had IgA l gammopathy; the
remaining two patients produced increased quantities of
kappa (one patient) or lambda (one patient) monoclonal
light chains. Nine MM patients excreted monoclonal
kappa light chains in urine and eight subjects excreted
monoclonal lambda light chains. Six patients did not excrete
monoclonal light chains; urinary analysis of immunoglobulin
light chains was not carried out in one patient who had free
monoclonal lambda chains in serum.
In all, 14 of the 24 MM patients (58%) excreted retinol in
urine, while only seven patients (29%) had elevated serum
creatinine; thus, urinary retinol excretion was a more
frequent sign of renal dysfunction than raised serum
creatinine (w2¼ 4.15, Po0.05). Five of those 14 retinol-
excreting patients had moderate or severe chronic renal
failure (CRF) (serum creatinine of 176.8–353.6 mmol/l, or
more than 353.6 mmol/l, respectively) (Table 2), while the
remaining nine retinol-excreting patients had normal serum
creatinine (Table 3). Average serum retinol-binding protein
(RBP) concentration, but not serum retinol, was significantly
higher in patients with moderate and severe CRF than in
normal subjects (t¼ 2.66, Po0.02 and t¼ 1.78, P¼ 0.1,
respectively). On the other hand, serum RBP and retinol
correlated highly (r¼ 0.969, Po0.007). The five moderate
and severe CRF patients excreted abundant quantities of RBP
in urine (392-fold more than control subjects (t¼ 17.55,
Po0.001). These patients also excreted 35 times more
protein (t¼ 9.59, Po0.001) and 94 times more albumin
(t¼ 7.21, P¼ 0.001) in urine than the healthy group. Urinary
retinol and RBP correlated highly (r¼ 0.973, Po0.006).
Nine other MM patients (Table 3), who also excreted
retinol in urine, had normal serum creatinine and their
serum RBP concentration did not differ significantly from
that of control subjects (t¼ 1.70, P40.1); however, they had
significantly lower serum retinol (t¼ 3.07, Po0.007). There
was a significant correlation between retinol and RBP in
serum (r¼ 0.713, Po0.032) and in urine in patients
(r¼ 0.997, Po0.001), and between urinary albumin and
urinary RBP (r¼ 0.678, Po0.05).
In all, 10 MM patients did not excrete measurable
quantities of retinol in urine and their urinary RBP was
similar to that of normal subjects (t¼ 0.48, P40.63). This
group included eight patients with normal serum creatinine
and two patients with mild CRF (serum creatinine of
89–168 mmol/l) (Table 4). Their average serum RBP concen-
tration did not differ from their control counterparts
(t¼ 0.14, P40.88). However, serum retinol concentration
in these MM patients, including the two patients with mild
CRF, was significantly lower than in healthy subjects
(t¼ 2.44, Po0.03). There was a significant correlation
between urinary RBP and albumin, and protein (r¼ 0.670,
Po0.034, and r¼ 0.667, Po0.036, respectively).
We examined a possible relationship between the type of
monoclonal light chains excreted and the excretion of retinol
and RBP in urine. The average (7s.d.) urinary RBP of nine
patients excreting kappa light chains was 0.03870.062 mmol/
mmol creatinine (six of them excreted retinol
0.04670.036 mmol/mmol creatinine). The urinary RBP of
eight patients who excreted lambda light chains was
0.05270.11 mmol/mmol creatinine (five of them excreted
retinol: 0.05570.091mmol/mmol creatinine). The difference
in urinary RBP or retinol between these groups was not
statistically significant (t¼ 0.77, P40.4; t¼ 0.923, P40.3,
respectively). Three of six patients who did not excrete Bence
Jones protein excreted retinol in very small quantities
(0.0056mmol and less per mmol creatinine). The serum
retinol of patients who excreted monoclonal light chains was
Table 1 | Serum and urine analytes in control group (n=10)
Variable Mean s.d. Range
Serum creatinine (mmol/l) 73.4 15.6 53–106
Serum retinol (mmol/l) 1.99 0.15 1.78–2.20
Serum RBP (mmol/l) 0.98 0.21 0.72–1.31
Urinary RBP/creatinine (nmol/mmol) 0.37 0.07 0.18–0.97
Urinary protein/creatinine (g/mmol) 0.01 0.006 0.006–0.026
Urinary albumin/creatinine (g/mmol) 0.0014 0.001 0.0007–0.0038
Table 2 | Serum and urine analytes in five MM patients with
moderate and severe CRF who excreted retinol in urine
Variable Mean s.d. Range
Serum creatinine (mmol/l) 390.0 162.4 182.1–592.3
Serum retinol (mmol/l) 3.20 2.22 1.43–6.88
Serum RBP (mmol/l) 3.14 2.65 1.27–7.81
Urinary retinol/creatinine (mmol/mmol) 0.098 0.065 0.055–0.211
Urinary RBP/creatinine (mmol/mmol) 0.145 0.113 0.043–0.325
Urinary protein/creatinine (g/mmol) 0.349 0.238 0.071–0.658
Urinary albumin/creatinine (g/mmol) 0.132 0.145 0.008–0.363
Table 3 | Serum and urine analytes in nine MM patients with
normal serum creatinine who excreted retinol in urine
Variable Mean s.d. Range
Serum creatinine (mmol/l) 63.1 22.0 32.7–83.1
Serum retinol (mmol/l) 1.62 0.34 1.01–2.09
Serum RBP (mmol/l) 0.82 0.21 0.55–1.16
Urinary retinol/creatinine (mmol/mmol) 0.008 0.015 0.001–0.047
Urinary RBP/creatinine (mmol/mmol) 0.0042 0.0067 0.001–0.022
Urinary protein/creatinine (g/mmol) 0.163 0.235 0.006–0.709
Urinary albumin/creatinine (g/mmol) 0.018 0.020 0.001–0.052
Table 4 | Serum and urine analytes in 10 MM patients who did
not excrete retinol in urine
Variable Mean s.d. Range
Serum creatinine (mmol/l) 85.1 35.8 47.7–163.5
Serum retinol (mmol/l) 1.73 0.30 1.29–2.09
Serum RBP (mmol/l) 0.97 0.28 0.57–1.32
Urinary RBP/creatinine (nmol/mmol) 0.35 0.20 0.05–0.70
Urinary protein/creatinine (g/mmol) 0.044 0.088 0.006–0.293
Urinary albumin/creatinine (g/mmol) 0.0038 0.0049 0.0009–0.0167
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higher than that of patients who did not (2.1171.30 vs
1.6670.41 mmol/l); however, this difference was not statisti-
cally significant (t¼ 0.81, P40.4).
Serum beta-2-microglobulin (b2M) (Table 5) in all MM
patient groups was significantly higher than in controls. b2M
serum level was the highest in MM patients with moderate
and severe CRF. Also, b2M was higher in patients with
normal serum creatinine who excreted retinol in urine than
in those who had no detectable urinary retinol. However, this
difference did not reach statistical significance. All MM
patient groups also excreted more b2M in urine than normal
subjects; these differences were significant for patients with
moderate and severe CRF and for patients with normal
serum creatinine who excreted retinol in urine. Urinary b2M
correlated with urine retinol and urine RBP in all patient
groups; these correlations were significant except for the
group with moderate/severe CRF, perhaps owing to the small
sample size (Table 6).
As MM patients may develop amyloidosis, we examined
bone marrow biopsies with Congo red staining. None of the
biopsies was positive for amyloidosis.
Of the seven hypertensive patients, two belonged to the
group of moderate/severe CRF (one of them had diabetes as
well), one patient (who also suffered from diabetes) belonged
to the group with normal serum creatinine who excreted
retinol in urine, and four patients belonged to those with no
detectable retinol in urine. All those patients did not differ
from the remaining patients of the respective groups.
DISCUSSION
Retinol circulates in the body bound to the 21 kDa plasma
RBP.12 In the plasma, RBP is mainly, up to 86%, bound to the
large protein, transthyretin.13 This protein–protein complex
mass is about 80 kDa and does not pass through the kidney
glomerulus. However, free RBP (not bound to transthyretin),
like other microglobulins, is readily filtrated through the
kidney glomerulus and reabsorbed by proximal tubular
epithelium.14 The fractional tubular reabsorption of RBP is
99.97%15 and it is therefore a sensitive marker of tubular
dysfunction, spilling over in the urine in the presence of
tubular damage. It has been shown that urinary RBP is a
good indicator of initial renal dysfunction in MM patients.16
Healthy subjects have no detectable quantities of retinol in
urine (Stephensen et al.17 and the present study). In contrast,
urinary retinol can be detected in patients with kidney
pathology.18 Retinol might be excreted also in the urine in
MM.10,11
The possible effect of retinol excretion on serum retinol
concentration in MM and the diagnostic value of urinary
retinol determination were objectives of our study. The
present investigation shows that retinol excretion in urine is a
common finding in MM, and that urinary retinol is a more
frequent indicator of renal dysfunction than elevated serum
creatinine in these patients. This is consistent with our
previous preliminary report.11 Adding the results of both
studies, 61% of 36 patients excreted retinol in urine, while
only 25% of them had elevated serum creatinine (w2¼ 9.57,
P¼ 0.002). This study shows that a strong and highly
significant correlation exists between urinary retinol and RBP
(r¼ 0.973, Po0.006), and that MM patients who do not
excrete retinol have urinary RBP similar to healthy subjects
(P40.63). This suggests that urinary retinol measurement is
of a diagnostic value similar to urinary RBP determination.
As compared with RBP, retinol determination is a more
readily available and less expensive test; thus, urinary retinol
analysis may be a more clinically convenient marker of renal
dysfunction than urine RBP.
Our study found no difference in the serum retinol
concentration between patients excreting and nonexcreting
monoclonal light chains. Also, there was no influence of the
type of excreted monoclonal light chains (kappa or lambda)
on the urinary excretion of retinol or RBP. Some MM
patients (three out of six) who did not excrete Bence Jones
protein excreted very small quantities of retinol in urine. It is
difficult to explain the mechanism of proximal tubule
dysfunction in these patients, but a similar phenomenon
was observed by Corso et al.,16 who found tubular or mixed
Table 5 | Serum and urine b2M in healthy and MM subjects
Serum b2M (lmol/l)
a Urine b2M/creatinine (nM/mM)
b
Group n Mean7s.d. Range Mean7s.d. Range
A. Healthy subjects 10 0.09670.027 0.04770.144 0.25970.231 0.017–0.744
B. MM patients with moderate/severe CRF who excreted retinol 5 0.45670.078 0.35570.562 151.1773.6 55.7–249.9
C. MM patients with normal serum creatinine who excreted retinol 9 0.37570.216 0.0977 0.793 26.75744.50 0.07–126.4
D. MM patients who did not excrete retinol 10 0.28970.241 0.10070.882 1.66973.488 0.006–11.5
aA vs B, C, D, Po0.03; C vs D, P40.15.
bA vs B, t=11.6, Po0.0001; A vs C, t=2.78, Po0.013; B vs C, t=3.04, P=0.01; B vs D, t=6.35, Po0.0001; C vs D, t=1.54, P=0.14.
Table 6 | Correlation between urine b2M and retinol, and







Group n r P r P
B. MM patients with moderate/
severe CRF who excreted retinol
5 0.725 40.16 0.712 40.17
C. MM patients with normal serum
creatinine who excreted retinol
9 0.857 o0.004 0.841 o0.005
D. MM patients who did not
excrete retinol
10 — — 0.648 o0.05
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glomerular–tubular proteinuria in some MM patients who
did not excrete Bence Jones protein.
b2M determination in urine is also valuable for the
diagnosis of renal proximal tubule damage.19 Urinary b2M in
patients with moderate/severe CRF and in patients with
normal serum creatinine who excreted retinol in urine was
significantly higher than in the control group. However, there
was no statistically significant difference in urinary b2M
between MM patients who did not excrete retinol in urine
and healthy subjects. We found a moderate correlation
between urinary b2M and retinol or RBP in patients with
moderate/severe CRF and in patients with normal serum
creatinine who excreted retinol in urine. Thus, results of b2M
excretion in urine are consistent with excretion of retinol and
RBP.
Massive proteinuria with high proportion of proteins
other than immunoglobulin light chain, such as albumin (as
observed in five of our patients with moderate/severe CRF),
might be a result of amyloidosis. However, there was no
evidence of systemic amyloidosis by Congo red staining of
bone marrow biopsies in our patients, although this does not
exclude the possibility of kidney amyloidosis. Also, light
chain deposition disease might be a cause of massive
proteinuria. However, the diagnosis of these two pathologies
requires renal biopsy, a procedure that can cause serious
complications such as hemorrhage and infection, and
therefore it is not performed routinely in our Hematology
Department. The possibility exists that comorbid diseases
(hypertension and diabetes) contributed to the massive
proteinuria in two of our MM patients. Circulating
permeability factors known to be involved in the develop-
ment of abnormal glomerular permeability to plasma
proteins20 might also be a reason for high albuminuria in
some of our MM patients.
The relationship between urinary and serum retinol in MM
patients is complex. Results from this study suggest that
excretion of retinol in urine is a factor contributing to the
hyporetinolemia in MM patients with normal and mildly
affected renal function. It is possible that a similar situation
occurs in the early phase of renal dysfunction of other
conditions such as diabetic nephropathy. However, other
mechanisms affecting retinol homeostasis may operate in renal
failure: the more profound decrease in the glomerular filtration
rate of patients with moderate and severe renal failure is
associated with hyper-retinolemia, in spite of considerable
retinol loss in their urine. We postulate that decreased
elimination of water-soluble retinyl-glucuronide and retinoyl-
glucuronide, similar to decreased glomerular filtration of
creatinine and urea, results in accumulation of retinol in
plasma in patients with considerable glomerular damage.
It is known that the proximal tubule is affected first in the
development of renal failure in MM patients, and that the
excessive excretion of immunoglobulin light chains plays a
central role in this process.4,5 Previously, we reported11 that
no correlation exists between urinary immunoglobulin light
chains and urinary retinol in MM patients. This suggests that
excretion of light chains in urine is most probably a result of
their hyperproduction rather than a consequence of proximal
tubule damage.
The presence of retinol in urine was indicative of renal
pathology, while a less clear-cut distinction exists between
normal and renal patients in regard to b2M and RBP
excretion.
In conclusion, the present study shows that (a) MM
patients excrete retinol in urine, (b) urinary retinol is a more
frequent marker of renal dysfunction than serum creatinine
in MM patients, (c) serum retinol is decreased in MM with
normal or mildly elevated serum creatinine and especially in
patients excreting retinol in urine, but not in patients with
moderate/severe renal failure, and (d) urinary retinol may
serve as a diagnostic marker of renal proximal tubule
dysfunction in MM patients.
Further studies are needed for a better understanding of
the retinol status in MM patients.
MATERIALS AND METHODS
In all, 24 MM patients (14 females and 10 males), average
age 65.0711.6 (mean7s.d.) years, were studied. None of them
received antimyeloma therapy at the time of the study: 11 patients
were newly diagnosed and the remaining 13 patients did not
receive specific treatment for at least a year. Seven of our MM
patients suffered from hypertension and two of them had type II
diabetes mellitus as well. In all, 10 healthy individuals (5 females, 5
males), aged 49.9713.1 (mean7s.d.) years, constituted the control
group.
Serum and urinary retinol was measured by high-performance
liquid chromatography methods already described,17,21 with minor
modifications. Serum and urine RBP, and b2M were determined by
enzyme-linked immunosorbent assay,22 also with minor modifica-
tions. Congo red staining of bone marrow biopsies was used for
amyloidosis diagnosis. Serum creatinine and urinary creatinine,
albumin, and protein were measured by routine laboratory
methods. Urinary analytes were normalized to urine creatinine.
Results are expressed as mean7s.d. Correlation between analytes
was estimated using the Pearson correlation test. Student’s unpaired
t-test was used for comparison of parameters in different groups.
MM patients had extreme values of urinary analytes; therefore,
logarithmic transformation (log10)
23 of urinary variables was
performed prior to t-test calculation. Comparison of the frequency
of elevated serum creatinine and of retinol excretion in urine was
evaluated by the w2 test. Probability levels o0.05 were considered
significant.
The institutional ethics committee for human investigations
approved the protocol of the study. Informed consent was obtained
from all patients and healthy participants.
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